Source comparison
Receptor Agonism vs Direct Hormone Replacement
MK-677 operates through ghrelin receptor agonism. Specifically binding to the growth hormone secretagogue receptor type 1a (GHSR-1a) located in the hypothalamus. This receptor normally responds to ghrelin, the 'hunger hormone' produced by the stomach, but MK-6
This comparison does not assign a generated winner or score.
- MK-677 operates through ghrelin receptor agonism. Specifically binding to the growth hormone secretagogue receptor type 1a (GHSR-1a) located in the hypothalamus. This receptor normally responds to ghrelin, the 'hunger hormone' produced by the stomach, but MK-677 is a non-peptide small molecule that mimics ghrelin's structure with higher affinity and longer half-life. Once bound, it triggers a cascade: increased GHRH secretion from hypothalamic neurons, amplified somatotroph activity in the pituitary, and elevated endogenous GH output. All while preserving the natural feedback loops that regulate pulse amplitude and frequency.
- Exogenous HGH injections contain recombinant human growth hormone (somatropin), identical in structure to endogenous GH but administered subcutaneously in doses ranging from 2–10 IU daily depending on research protocol. This bypasses the hypothalamic-pituitary axis entirely. The exogenous hormone binds directly to GH receptors in target tissues. Liver (stimulating IGF-1 production), muscle, adipose tissue, bone. Without requiring any upstream signaling. The pituitary interprets the elevated serum GH as overproduction and responds by downregulating somatotroph activity through negative feedback mediated by somatostatin release. Within 7–10 days of consistent HGH administration, endogenous GH pulse frequency drops by 60–80%, and pulsatile secretion can take 4–8 weeks to normalize after cessation.